Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: The Lung-MAP S1400I phase 3 randomized clinical trial

JAMAGettinger SN, Redman MW, Bazhenova L, et al. | July 19, 2021

Advertisement

Researchers aimed at examining if the addition of ipilimumab to nivolumab results in improvement in survival of patients with advanced chemotherapy-pretreated immunotherapy-naive squamous cell lung cancer. They conducted the Lung Cancer Master Protocol (Lung-MAP) S1400I phase 3, open-label randomized clinical trial including 252 patients. Findings revealed no correlation of adding ipilimumab to nivolumab with improved survival in patients with advanced chemotherapy-pretreated squamous cell carcinoma. In patients with advanced non–small cell lung cancer, currently combination therapy with nivolumab and ipilimumab is only indicated as first-line therapy.

Read the full article on JAMA

Advertisement